VanEck Biotech ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
VanEck Biotech ETF BBH
Morningstar’s Analysis BBH
Will BBH outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 72.3
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Amgen Inc | 15.75 | 77M | Healthcare |
Gilead Sciences Inc | 13.15 | 64M | Healthcare |
Vertex Pharmaceuticals Inc | 8.20 | 40M | Healthcare |
Regeneron Pharmaceuticals Inc | 6.49 | 32M | Healthcare |
Moderna Inc | 6.05 | 30M | Healthcare |
Natera Inc | 5.33 | 26M | Healthcare |
argenx SE ADR | 4.58 | 22M | Healthcare |
IQVIA Holdings Inc | 4.46 | 22M | Healthcare |
Revolution Medicines Inc Ordinary Shares | 4.21 | 21M | Healthcare |
Illumina Inc | 4.04 | 20M | Healthcare |